bismuth has been researched along with pantoprazole in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bardhan, KD | 1 |
| Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG | 1 |
| Andriulli, A; Annese, V; Niro, GA; Perri, F; Quitadamo, M; Villani, MR | 1 |
| Bermejo, F; Boixeda, D; Defarges, V; García-Plaza, A; Hernández-Ranz, F; López-Sanromán, A; Martín-De-Argila, C; Milicua, JM | 1 |
| de Boer, SY; de Boer, WA; Siem, H; v d Meeberg, PC | 1 |
| Andriulli, A; Barberani, F; Festa, V; Merla, A; Perri, F; Pilotto, A | 1 |
| Altintaş, E; Sezgin, O; Tataroğlu, C; Uçbilek, E | 1 |
| Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Kim, SG; Lee, DH; Song, IS | 1 |
| Kadayifçi, A | 1 |
| Buzás, GM; Széles, I | 1 |
| Demir, M; Gokturk, HS; Ozturk, NA; Serin, E; Yilmaz, U | 1 |
| Demir, M; Göktürk, S; Oztürk, NA; Serin, E; Yilmaz, U | 1 |
| Choi, KD; Chung, JW; Jung, HY; Kim, JH; Lee, GH; Lee, JH; Oh, TH; Song, HJ; Yun, SC | 1 |
| Cuccu, M; Dore, MP; Farina, V; Graham, DY; Mameli, L; Massarelli, G | 1 |
| Bari, Z; Fakheri, H; Hosseini, V; Taghvaei, T | 1 |
| Bari, Z; Fakheri, H; Sardarian, H | 1 |
| Ataseven, H; Baglıcakoglu, M; Biyik, M; Demir, A; Goktepe, H; Gungor, G; Kayacetin, E; Ucar, R | 1 |
| Cellini, L; Ciccaglione, AF; Grossi, L; Manzoli, L; Marzio, L; Tavani, R | 1 |
| Chen, CL; Hsu, PI; Kao, JY; Kao, SS; Pan, CY; Peng, NJ; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC | 1 |
1 review(s) available for bismuth and pantoprazole
| Article | Year |
|---|---|
Triple therapy as a cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 1996 |
15 trial(s) available for bismuth and pantoprazole
| Article | Year |
|---|---|
Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Clarithromycin; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Pantoprazole; Ranitidine; Sulfoxides; Tinidazole | 2000 |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Ranitidine; Recurrence; Sulfoxides; Tinidazole; Treatment Outcome; Urea | 2001 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Pantoprazole; Peptic Ulcer; Prospective Studies; Sulfoxides; Tetracycline; Treatment Failure; Treatment Outcome | 2002 |
Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Sulfoxides; Tetracycline | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Pantoprazole; Prospective Studies; Ranitidine; Sulfoxides; Tinidazole; Treatment Failure; Urea | 2003 |
Bismuth-based therapies for the first step eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Ranitidine; Tetracycline; Treatment Outcome; Urease; Young Adult | 2006 |
Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Contraindications; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pantoprazole; Pyloric Antrum; Stomach Ulcer; Tetracycline; Treatment Failure | 2006 |
Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Cross-Over Studies; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Ranitidine; Urea | 2008 |
Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Ranitidine | 2009 |
Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Case-Control Studies; Chi-Square Distribution; Clarithromycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Statistics, Nonparametric; Surveys and Questionnaires; Tetracycline; Treatment Outcome | 2010 |
Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Male; Medication Adherence; Metronidazole; Middle Aged; Pantoprazole; Prospective Studies; Tetracycline; Time Factors; Treatment Outcome; Urea | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histocytochemistry; Humans; Italy; Male; Metronidazole; Middle Aged; Pantoprazole; Prospective Studies; Tetracycline; Time Factors; Treatment Outcome; Urea; Young Adult | 2011 |
A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Iran; Male; Middle Aged; Organometallic Compounds; Pantoprazole | 2012 |
A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Treatment Failure; Treatment Outcome; Young Adult | 2012 |
Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Bismuth; Breath Tests; Clinical Protocols; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Salicylates; Turkey | 2015 |
3 other study(ies) available for bismuth and pantoprazole
| Article | Year |
|---|---|
What is the best first choice treatment option for Helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Humans; Medication Adherence; Metronidazole; Pantoprazole; Tetracycline | 2007 |
Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Pantoprazole; Pilot Projects; Proton Pump Inhibitors; Rifabutin; Salvage Therapy; Treatment Outcome | 2016 |
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Adult; Anti-Bacterial Agents; Bacteroidetes; Bismuth; Drug Therapy, Combination; Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proteobacteria; Proton Pump Inhibitors; Tetracycline; Young Adult | 2018 |